DRUG METABOLISM REVIEWS

Scope & Guideline

Advancing knowledge in pharmacology and toxicology.

Introduction

Welcome to the DRUG METABOLISM REVIEWS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of DRUG METABOLISM REVIEWS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0360-2532
PublisherTAYLOR & FRANCIS LTD
Support Open AccessNo
CountryUnited States
TypeJournal
Converge1972, from 1974 to 2024
AbbreviationDRUG METAB REV / Drug Metab. Rev.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND

Aims and Scopes

The journal 'Drug Metabolism Reviews' serves as a vital resource for researchers and professionals in pharmacology, toxicology, and drug development, focusing on the complexities of drug metabolism and disposition. Its aims and scopes encompass a wide range of topics within drug metabolism, with an emphasis on both fundamental and applied aspects.
  1. Drug Metabolism Mechanisms:
    Explores the biochemical processes and enzymatic pathways involved in the metabolism of drugs, including phase I and phase II reactions, and the role of cytochrome P450 enzymes.
  2. Pharmacogenetics and Drug Interactions:
    Investigates the genetic factors influencing drug metabolism and the implications of drug-drug and drug-gene interactions on therapeutic outcomes and adverse effects.
  3. Transport Mechanisms in Drug Disposition:
    Focuses on the role of drug transporters in pharmacokinetics, including absorption, distribution, and elimination processes, and their impact on drug efficacy and safety.
  4. Toxicology and Hepatotoxicity:
    Addresses the potential toxic effects of drugs and their metabolites, particularly focusing on hepatotoxicity and the mechanisms underlying drug-induced liver injury.
  5. Biotransformation Research:
    Covers advances in biotransformation studies, including novel methodologies for assessing drug metabolism and the development of predictive models for drug interactions.
  6. Regulatory and Clinical Implications:
    Discusses regulatory guidelines and clinical considerations related to drug metabolism, including in vitro and in vivo methodologies and their translation to clinical practice.
The journal has exhibited a dynamic evolution in its research themes, reflecting the latest advancements in drug metabolism science. This section outlines the trending and emerging scopes that are gaining traction in recent publications.
  1. Pharmacogenomics and Personalized Medicine:
    There is a notable increase in research exploring pharmacogenomics, emphasizing how genetic variations affect drug metabolism and response, thereby supporting the movement towards personalized medicine.
  2. Drug Transporter Studies:
    Emerging interest in the role of drug transporters in drug disposition and interactions is evident, highlighting their significance in pharmacokinetics and the blood-brain barrier.
  3. Innovative Drug Delivery Systems:
    Research on novel drug delivery systems, including nanocarriers and biopolymers, is trending, focusing on improving bioavailability and targeting specific sites, particularly in cancer therapy.
  4. Impact of Gut Microbiota on Drug Metabolism:
    An increasing number of studies are exploring how gut microbiota influences drug metabolism and pharmacokinetics, signifying a growing recognition of the microbiome's role in drug response.
  5. Advanced In Vitro and In Vivo Models:
    The development of sophisticated in vitro and in vivo models for studying drug metabolism and toxicity is on the rise, as researchers seek better predictive tools for clinical outcomes.

Declining or Waning

While 'Drug Metabolism Reviews' continues to be a leading journal in the field, certain themes have shown a decline in focus or frequency of publication. This section highlights these waning scopes, indicating shifts in research priorities or emerging interests.
  1. Natural Product Drug Interactions:
    Research on the pharmacokinetic interactions involving natural products has decreased, possibly due to a growing emphasis on synthetic drug development and biopharmaceuticals.
  2. General Toxicogenomics:
    While still relevant, the broad application of toxicogenomics in drug metabolism studies has seen a reduction in publications, as researchers increasingly focus on specific mechanisms and pathways.
  3. Traditional Pharmacokinetics:
    The traditional approaches to pharmacokinetics are being overshadowed by novel methodologies and advanced technologies, leading to fewer publications centered on classical pharmacokinetic principles.
  4. Basic Mechanisms of Drug Resistance:
    Studies focused solely on the basic mechanisms of drug resistance, without integration into broader clinical or translational contexts, have become less frequent as the field shifts towards targeted therapies and personalized medicine.

Similar Journals

CHEMICO-BIOLOGICAL INTERACTIONS

Connecting Research for a Safer Tomorrow
Publisher: ELSEVIER IRELAND LTDISSN: 0009-2797Frequency: 18 issues/year

CHEMICO-BIOLOGICAL INTERACTIONS is a premier journal published by Elsevier Ireland Ltd, dedicated to advancing the field of chemical and biological interactions since its inception in 1969. With a robust focus on pharmacology and toxicology, the journal holds a prestigious Q1 ranking in both Medicine (miscellaneous) and Toxicology, reflecting its significance in disseminating influential research. As part of the Scopus database, it ranks #21 out of 133 journals in Toxicology, positioning it in the 84th percentile and ensuring high visibility for cutting-edge studies. This scholarly platform serves as a crucial resource for researchers, professionals, and students who seek reliable and innovative findings at the intersection of chemistry and biology. While currently not open access, CHEMICO-BIOLOGICAL INTERACTIONS provides a comprehensive collection of articles that contribute to the ongoing dialogue in toxin research and its implications on medicinal chemistry, thereby fostering advancements in public health and safety.

European Journal of Pharmacology

Elevating pharmacological knowledge for global healthcare progress.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

ADMET and DMPK

Fostering collaboration in the evolving landscape of medicinal chemistry.
Publisher: IAPC PUBLISHINGISSN: 1848-7718Frequency: 4 issues/year

ADMET and DMPK is a premier open-access journal published by IAPC PUBLISHING since 2013, focusing on the rapidly evolving fields of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK (Drug Metabolism and Pharmacokinetics). Catering to researchers, professionals, and students in the realms of pharmacology, toxicology, and medicinal chemistry, this journal plays a crucial role in fostering innovation and collaboration within the interdisciplinary landscape of drug development. With an impressive Q1 ranking in Pharmacology, Toxicology and Pharmaceutics and ranking in the top percentiles across various categories such as Chemistry and Health, ADMET and DMPK provides a reputable platform for high-quality publications. Its global reach, complemented by its open-access model, ensures that valuable research is accessible to a wide audience. As we converge towards 2024, this journal remains dedicated to advancing knowledge and practices that shape the future of drug discovery and safety, making it an essential resource in the scientific community.

Expert Opinion on Drug Metabolism & Toxicology

Transforming Knowledge into Practice in Toxicology
Publisher: TAYLOR & FRANCIS LTDISSN: 1742-5255Frequency: 12 issues/year

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

Current Drug Safety

Championing Research for Public Health and Safety
Publisher: BENTHAM SCIENCE PUBLISSN: 1574-8863Frequency: 3 issues/year

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

DRUGS IN R&D

Catalyzing discoveries in drug research and development.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

DRUG METABOLISM AND DISPOSITION

Pioneering Discoveries in Pharmacological Science
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0090-9556Frequency: 12 issues/year

Drug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Advancing the Frontiers of Pharmacology and Physiology
Publisher: WILEYISSN: 0305-1870Frequency: 12 issues/year

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

BIOPHARMACEUTICS & DRUG DISPOSITION

Empowering Discoveries in Biopharmaceutics
Publisher: WILEYISSN: 0142-2782Frequency: 6 issues/year

BIOPHARMACEUTICS & DRUG DISPOSITION, published by WILEY, is a prominent journal in the fields of biopharmaceutics and pharmacology, dedicated to the dissemination of vital research that spans from the foundational aspects of drug disposition to advanced therapeutic developments. Since its inception in 1979, this journal has established itself as a crucial resource for a diverse audience, including researchers, professionals, and students. With its impact factor indicating solid performance and a current ranking in Q2 for Pharmaceutical Science and Q3 across miscellaneous medicine categories, BIOPHARMACEUTICS & DRUG DISPOSITION serves as a nexus for innovative studies and breakthrough findings. The journal's comprehensive scope ensures that rigorous scientific inquiry is represented, helping to advance the understanding of drug behavior in biological systems. Participating in this scholarly dialogue not only enhances individual knowledge but contributes to the broader pharmaceutical and medical communities, making it an essential publication for all stakeholders interested in drug development and utilization.

International Journal of Pharmacology

Advancing the Frontiers of Pharmacological Research
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.